Nippon India Nifty Pharma ETF

Nippon India Mutual Fund · Equity ETFs · Direct Growth · AMFI 149008 · ISIN INF204KC1089
NAV₹29.186320 Nov 2026
3Y return+22.02%a year
5Y return+16.60%a year
Expense ratio0.23%₹1,756 Cr
Growth Score—

Returns

1M3M6MYTD1Y3Y5Y7Y10YSince launch
Fund+10.82%+7.43%+14.54%+25.40%+25.57%+22.02%+16.60%——+14.02%
NIFTY Pharma TRI+10.85%+7.49%+14.67%+25.66%+25.86%+22.31%+16.87%———
Category middle+9.21%+2.42%+8.27%+2.25%+1.02%+14.23%+11.71%+14.45%+13.56%—

Risk (36 months)

Volatility14.96%
Sharpe1.04
Sortino1.72
Beta1.00
Alpha+0.00%
Deepest fall-20.98%
1-year periods with a loss26%
5Y SIP XIRR+20.60%

Top holdings (31 Oct 2026)

Sun Pharmaceutical Industries Limited18.61%
Divi's Laboratories Limited12.28%
Laurus Labs Limited9.26%
Dr. Reddy's Laboratories Limited8.15%
Cipla Limited7.67%
Torrent Pharmaceuticals Limited6.71%
Lupin Limited4.83%
Aurobindo Pharma Limited4.59%
Glenmark Pharmaceuticals Limited3.42%
Zydus Lifesciences Limited3.05%
Alkem Laboratories Limited3.05%
Mankind Pharma Limited2.79%

Sectors

Pharmaceuticals & Biotechnology100.0%

Calculated by Growth Analyser from AMFI NAVs and the fund house's disclosed portfolio. Up to 1 year: total return; longer: CAGR. Research and education only; not investment advice. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not indicate future returns.